JJ
VTGN icon

Johnson & Johnson’s VistaGen Therapeutics VTGN Stock Holding History

Johnson & Johnson’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,350
Closed -$23.8K – 23
2023
Q1 		$23.8K Buy
+6,350
New +$33.3K 0.01% 22

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Johnson & Johnson's VTGN Position: Q2 2023 in Review

Johnson & Johnson sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 6,350 shares — an estimated $23.8K sold.

Johnson & Johnson first reported a position in VTGN in Q1 2023 and held it in 1 quarter. The position peaked at $23.8K in Q1 2023. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Johnson & Johnson reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Johnson & Johnson sold 6,350 VistaGen Therapeutics shares in Q2 2023, an estimated $23.8K.
  • Johnson & Johnson first reported a position in VistaGen Therapeutics in Q1 2023 and held it in 1 quarter.
  • Johnson & Johnson's VistaGen Therapeutics position peaked at $23.8K in Q1 2023.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Johnson & Johnson's 13F filing for Q2 2023, filed 2 Aug 2023.